Shares of Sun Pharmaceuticals were trading with mild gains after the company announced settlement of patent litigation for generic Revlimid in the US.
"
NSE -0.15 % has reached an agreement with Celgene Corporation (Celgene), a wholly-owned subsidiary of Bristol Myers Squibb, to resolve the patent litigation regarding submission of an Abbreviated New Drug Application (ANDA) for a generic version of Revlimid